Full-Time

Director/Senior Director

Voyager Therapeutics

Voyager Therapeutics

51-200 employees

Develops gene therapies for neurological disorders

Biotechnology

Senior, Expert

Lexington, MA, USA

Requirements
  • PhD in chemistry, biochemistry, chemical biology, or a related field with at least 10 years of industry experience
  • Demonstrated leadership and management experience with a track record of leading teams and projects to successful endpoints and commercialization
  • Experience with bioconjugation of enzymes and oligonucleotides
  • Deep experience with peptide and protein chemistry with emphasis on optimization of in vivo properties
  • Experience in developing nucleic acid-based therapeutics
  • Experience in CNS delivery strongly preferred
  • Ability to build and maintain collaborations with industry and academic partners
  • Expertise in intellectual property protection and expansion
  • Familiarity with in vitro and/or in vivo screening methods
  • Strong collaboration and stakeholder management skills
Responsibilities
  • Leverage vast knowledge in peptide chemistry, oligonucleotide chemistry and conjugation chemistry to discover, engineer or improve performance of existing and future compounds
  • Manage a high-performance group of scientists and researchers
  • Manage and lead projects in a matrixed environment
  • Ability to mentor, retain and recruit top talent
  • Provide strategic direction and leadership in all areas of chemical biology

Voyager Therapeutics stands out in the biotechnology industry for its pioneering work in gene therapy and neurology, particularly in overcoming delivery challenges that have historically limited the potential of these disciplines. The company's TRACER AAV capsid discovery platform, which has generated novel capsids with high target delivery and blood-brain barrier penetration, is not only advancing Voyager's own pipeline of preclinical programs in Parkinson's disease, Alzheimer's disease, and ALS, but also fueling partnerships with industry leaders like Pfizer, Novartis, and Neurocrine Biosciences. Voyager's commitment to diversity and collaboration further enhances its competitive edge, fostering an inclusive culture that values different perspectives and is dedicated to making discoveries that can change the course of medicine for patients.

Company Stage

IPO

Total Funding

$344M

Headquarters

Cambridge, Massachusetts

Founded

2014

Growth & Insights
Headcount

6 month growth

8%

1 year growth

39%

2 year growth

47%